AbstractHeart failure (HF) is a major public health issue with a current prevalence of over 5.8 million in the USA and over 23 million worldwide. Ischemic heart disease is known to be the most important risk factor for HF. Ivabradine is a new therapeutic agent designed to reduce heart rate at rest and during exercise by selective inhibition of a novel receptor (If channel) located on the pacemaker-cell membrane within the sinoatrial node. As such, ivabradine joins a list of rate-limiting medications already available to prescribers for the control of heart rate in coronary artery disease (CAD) and HF with systolic dysfunction. The ω-3 polyunsaturated fatty acids (PUFA), such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), are used for HF treatment. The objective of the research was to evaluate the dynamics of innate immunity parameters in patients with ischemic HF by treatment with ivabradine and ω-3 polyunsaturated fatty acids. Material and Methods. 357 patients with ischemic HF and preserved sinus rhythm were observed. All the patients were divided into four groups according to their treatment. Physical examinations were performed. The functional activity of neutrophils and lymphocytes was examined. Conclusions. All used therapeutic schemes influenced unstimulated activity of lymphocytes only, which was caused by normalization of the general condition and some decline in inflammation.
Murray C.J.L., Vos T., Lozano R., et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380: 2197-2223.
Yusuf S., Rangarajan S., Teo K. et al. Cardiovascular Risk and Events in 17 Low-, Middle-, and High-Income Countries. NEJM. 2014; 371: 818-827.
Ambrosy A.P., Fonarov G.C., Butler J. et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from HHF registres. J. Am. Coll. Cardiol. 2014; 63: 1123-1133.
Hofmann U., Frantz S. How we can cure a heart “in flame”? A translation view on inflammation in heart failure. Basic. Res. Cardiol. 2013; 108: 2-19.
European Medicines Agency. ICH Harmonised Tripartite Guideline E6: Note for Guidance on Good Clinical Practice (PMP/ICH/135/95). London: European Medicines Agency. 2002: 46.
Laboratory investigations in clinical immunology: methods, pitfails and clinical indications: a second IUIS WHO report. Clin. Immunol. Immunopathol. 1988; 49: 478-497.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.